Treatment of dwarfism with recombinant human insulin-like growth factor-1;Übersichtsarbeit: Behandlung des kleinwuchses mit rekombinantem humanem "insulin-like growth factor-1"

Deutsches Arzteblatt

Volumn 106, Issue 43, 2009, Pages 703-709

  Ranke, Michael B ^a   Wölfle, Joachim ^b   Schnabel, Dirk ^c   Bettendorf, Markus ^d  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Developmental disorder; Dwarfism; Growth; Hormonal therapy; Pediatric disease

Indexed keywords

GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADENOIDAL HYPERTROPHY; BODY HEIGHT; CARTILAGE CELL; CELL DIFFERENTIATION; CELL GROWTH; CHILD; CLINICAL TRIAL; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DWARFISM; EPIPHYSIS PLATE; FOOD INTAKE; GENETIC ANALYSIS; GROWTH RATE; GROWTH STIMULATION; HEADACHE; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; HYPERTROPHY; HYPOGLYCEMIA; HYPOPHYSIS; INJECTION SITE PAIN; INJECTION SITE REACTION; INSULIN LIKE GROWTH FACTOR 1 DEFICIENCY; INTRACRANIAL HYPERTENSION; LARON SYNDROME; LIPOHYPERTROPHY; MEDLINE; MOLECULAR GENETICS; PAPILLEDEMA; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; REVIEW; SHORT STATURE; SLEEP APNEA SYNDROME; THYMUS HYPERPLASIA; TONSIL DISEASE; TONSILLAR HYPERTROPHY;

DWARFISM; HUMANS; INSULIN-LIKE GROWTH FACTOR I; RECOMBINANT PROTEINS;

EID: 74549225181     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2009.0703     Document Type: Review

References (25)

1. LeRoith D, Bondy C, Yakar S, Jun-Li Liu J-L, Butler A: The somatomedin hypothesis: Endocr Rev 2001; 22: 53-74.
2. Ranke MB: Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance. Trends Endocrinol Metab 2005; 16: 190-7.
3. Carro E, Trejo JL, Núñez A, Torres-Aleman I: Brain repair and neuroprotection by serum insulin-like growth factor I. Mol Neurobiol 2003; 27: 153-62.
4. Vincent AM, Mobley BC, Hiller A, Feldman EL: IGF-1 prevents glutamate-induced motor neuron programmed cell death. Neurobiol Dis 2004; 16: 407-16.
5. Festoff BW: Amyotrophic lateral sclerosis: current and future treatment strategies. Drugs 1996; 51: 28-44.
6. Blum WF, Cotterill AM, Postel-Vinay MC, Ranke MB, Savage MO, Wilton P: Improvement of diagnostic criteria in growth hormone insensitivity syndrome: solutions and pitfalls. Pharmacia Study Group on insulin-like growth factor I treatment in growth hormone insensitivity syndromes. Acta Paediatr Suppl 1994; 399: 117-24.
7. Savage MO, Blum WF, Ranke MB, et al.: Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome). J Clin Endocrinol Metab 1993; 77: 1465-71.
8. Schwarze CP, Wollmann HA, Binder G, Ranke MB: Short-term increments of insulin-like growth factor I (IGF-1) and IGF-binding protein-3 predict the growth response to growth hormone (GH) therapy in GH-sensitive children. Acta Paediatr Suppl 1999; 88: 200-8.
9. Buckway CK, Guevara-Aguirre J, Pratt KL, Burren CP, Rosenfeld RG: The IGF-1 generation test revisited: a marker of GH sensitivity. J Clin Endocrinol Metab 2001; 86: 5176-83.
10. Selva KA, Buckway CK, Sexton G, et al.: Reproducibility in patterns of IGF generation with special reference to idiopathic short stature. Horm Res 2003; 60: 237-46.
11. Jorge AA, Souza SC, Arnhold IJ, Mendonca BB: Poor reproducibility of IGF-1 and IGF binding protein-3 generation test in children with short stature and normal coding region of the GH receptor gene. J Clin Endocrinol Metab 2002; 87: 469-72.
12. Goddard AD, Covello R, Luoh SM, et al.: Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group. N Engl J Med 1995; 333: 1093-8.
13. Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J: Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994; 15: 369-90.
14. Klinger B, Laron Z: Three year IGF-1 treatment of children with Laron syndrome. J Ped Endocrinol Metab 1995; 8: 149-58.
15. Guevara A, Vasconez O, Martinez V, et al.: A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab 1995; 80: 1393-8.
16. Ranke MB, Savage MO, Chatelain PG, et al.: Insulin-like growth factor I improves height in growth hormone insensitivity: two years' results. Horm Res 1995; 44: 253-64.
17. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P: Long-term treatment of growth hormone insensitivity syndrome with IGF-1. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res 1999; 51: 128-34.
18. Backeljauw PF, Underwood LE: Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome - a clinical research center study. GHIS Collaborative Group. J Clin Endocrinol Metab 1996; 81: 3312-7.
19. Backeljauw PF, Underwood LE: Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab 2001; 86: 1504-10.
20. Chernausek SD, Backeljauw FB, Frane J, Kuntze J, Underwood LE for the GH Insensitivity Syndrome Collaborative Group: Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-1 deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007; 92: 902-10.
21. Collett-Solberg PF, Misra M, on behalf of the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society: The role of recombinant human insulin-like growth factor-I in treating children with short stature. J Clin Endocrinol Metab 2008; 93: 10-8.
22. Cohen P, Clemmons DR, Rosenfeld RG: Does the GH-IGF axis play a role in cancer pathogenesis? Growth Hormone IGF Res 2000; 10: 297-305.
23. Sachdev D, Yee D: Disrupting insulin-like growth factor signalling as a potential cancer therapy. Mol Cancer Ther 2007; 6: 1-12.
24. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, et al.: Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab 1997; 82: 629-33.
25. Woelfle J, Chia DJ, Massart-Schlesinger MB, Moyano P, Rotwein P: Molecular physiology, pathology, and regulation of the growth hormone/insulin-like growth factor-I system. Pediatr Nephrol 2005; 20: 295-302.